Six months is a long time in oncology, but in inflammatory disease it is an eternity — and Celldex’s Phase 3 CSU program enrolling 1,939 patients that far ahead of guidance says something concrete about site enthusiasm and patient unmet need that no press release framing can manufacture. EMBARQ-CSU1 and EMBARQ-CSU2 together represent the largest randomized trial ever run in antihistamine-refractory chronic spontaneous urticaria, and that scale matters for regulatory credibility: FDA will have statistical power to cut the data across prior therapy strata, including the advanced-therapy-experienced subgroup that dupilumab and omalizumab largely leave behind.
The more clinically interesting signal, though, is the sustained off-treatment efficacy reported in Phase 2 CSU patients treated for the full 52 weeks — tryptase normalized, barzolvolimab cleared, yet disease control persisted. That is not symptomatic suppression. That is a biology-altering effect on mast cell populations, and if the Phase 3 data replicate it, the label discussion shifts from maintenance dosing to intermittent retreatment. Payers hate open-ended biologics; a retreatment paradigm with defined cycles changes the pharmacoeconomic argument entirely. The cold urticaria retreatment data reinforce the same point: second exposure produced efficacy comparable to first, which removes the concern that mast cell depletion induces compensatory repopulation with reduced drug sensitivity.
CDX-622, the SCF/TSLP bispecific, is the asset that deserves more attention than it is getting. Blocking TSLP alone is Amgen’s tezepelumab territory; depleting mast cells via SCF starvation simultaneously is a mechanistic combination that neither dupilumab nor tezepelumab attempts. The Phase 1 proof-of-mechanism study in mild-to-moderate asthma, using blood and skin pharmacodynamic biomarkers as primary readouts, is essentially a surrogate-endpoint stress test — if CDX-622 demonstrably collapses tissue mast cell counts while suppressing Type 2 signaling in the same patients, Celldex has a scientific basis for a broad inflammatory fibrosis program that goes well beyond urticaria. The $345 million raise gives them runway to find out without partnering prematurely.
The single number that will define the next twelve months is the UAS7 weekly urticaria activity score reduction in EMBARQ-CSU1 topline data, expected Q4 2026. If barzolvolimab’s Phase 3 effect size matches or exceeds its Phase 2 performance in the advanced-therapy-refractory subgroup specifically, the BLA filing in 2027 carries a differentiated label argument — not just another anti-IgE or anti-IL-4 receptor mechanism, but among the first approved mast cell depleters in CSU.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
